Trial Profile
A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Jun 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 08 Jun 2021 Results published in the Journal of Thoracic Oncology
- 18 Dec 2020 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Primary endpoint (Progression-free survival rate) has not been met.